Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Panelists at this year’s Transcatheter Cardiovascular Therapeutics symposium debate whether left atrial appendage occlusion device makers can compete against anti-coagulant drug makers, which have long held a coveted spot as the gold standard in stroke prevention for patients with atrial fibrillation.
German medical device maker Transcatheter Technologies GmbH announces 1st-in-man implantation of its repositionable Trinity transcatheter aortic valve system, treading into territory already marked by medtech giants Medtronic and St. Jude Medical.
Makers of atrial appendage occlusion devices sound off on whether the implants should continue to rely on hooks for anchoring, like St. Jude Medical’s Amplatzer Amulet does, or find novel ways to keep the devices in place, the way some new device makers propose.